Protein kinase B (AKT)-driven proteasome targeting was found to reduce DTPs in breast, lung and ovarian cancer cells harboring phosphatase and tensin homolog (PTEN)/phosphoinositide 3-kinase (PI3K) pathway mutations [112]. Here, AKT1 is linked to ovarian cancer.